ADJUVANT AND VIRUS-FREE VACCINES

2 CANDIDATES IN PRECLINICAL DEVELOPMENT
AGAINST CHIKUNGUNYA AND ZIKA

Ciloa is currently developping in preclinical phase, 2 candidates against Chikungunya virus (FUI granted) and Zika. These candidate vaccines are virus-free and adjuvant-free.

These first prototypes will validate Ciloa’s platform of a new generation of vaccines. In case of pandemic, this will be a unique tool to develop efficient preventive vaccines on time.

CLASSICAL TECHNOLOGICAL CONSTRAINTS

  • Use attenuated virus, or inactivated virus, or Viral-Like-Particles
  • Artificial adjuvants required to boost immune response
  • Adverse side effects, some being severe

Thus, current technologies are not well-adapted to pregnant women & immuno-compromised people.

OVERCOME TECHNOLOGICAL LOCKS

The benefits to use Ciloa’s recombinant exosomes

Ciloa has the sole technology that enables to develop safe & intelligent vaccines based on recombinant exosomes.

  • No need of viruses (attenuated or inactivated), nor viral pseudo-particles
  • No need of artificial adjuvants, thanks to the properties of exosomes
  • Easy and rapid implementation on exosome platform of a new antigen  in the event of a pandemic.
With Ciloa approach, knowledge of the gene sequence is the only requirement for producing antigen-bearing exosomes allowing efficient protective vaccination.

Exosomes are known to activate immune responses through various mechanisms, including transfering antigens to dendritic cells, presentating antigens to T lymphocytes, and activating natural killer cells.

In addition, several functional co-stimulatory molecules naturally present on exosomes are able to enhance immune responses. Thus, exosomes presenting antigens trigger efficient protection without any added adjuvants.

No pathogens are necessary to develop vaccines against tumor cells, viruses, bacteria or parasites using membrane proteins (GPCRs, viral envelope proteins …) sorted with their native conformation on exosomes.

The combination of both, a perfect antigen and a potent natural adjuvant effect leads to the perfect candidate vaccine.

As cell-free nanovesicules that do not require the use of a viral machinery for assembly,  exosome-based vaccines offer a high bio-safety profile. The scale-up of exosome based vaccines for clinical assays, has been already reported.

Menu